# Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Canonical URL: https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-first-quarter-2026-financial-results-and-highlights-recent-activity
Ticker: IKT
Company: Inhibikase Therapeutics
Source: Inhibikase Therapeutics
Published: 2026-05-12 20:01 EST
Original Source URL: https://www.inhibikase.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-12 20:01 EST — [Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-first-quarter-2026-financial-results-and-highlights-recent-activity) — Source: Inhibikase Therapeutics
- 2026-04-07 12:00 EST — [Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension) — Source: Inhibikase Therapeutics
- 2026-04-03 18:01 EST — [Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Inhibikase Therapeutics
- 2026-03-26 20:01 EST — [Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-full-year-2025-financial-results-and-highlights-recent-activity) — Source: Inhibikase Therapeutics
- 2025-11-21 02:54 EST — [Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-pricing-of-100-million-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Inhibikase Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)